| First Author | Yu D | Year | 2019 |
| Journal | Int Immunopharmacol | Volume | 73 |
| Pages | 312-320 | PubMed ID | 31129418 |
| Mgi Jnum | J:289878 | Mgi Id | MGI:6435076 |
| Doi | 10.1016/j.intimp.2019.04.035 | Citation | Yu D, et al. (2019) Rev-erbalpha can regulate the NF-kappaB/NALP3 pathway to modulate lipopolysaccharide-induced acute lung injury and inflammation. Int Immunopharmacol 73:312-320 |
| abstractText | Progressive lung injury and pulmonary inflammation can be induced by an intraperitoneal injection of lipopolysaccharide (LPS). Interleukin-1beta (IL-1beta) is a key pro-inflammatory cytokine that can further exaggerate inflammation, which is cleaved and activated by the NALP3 inflammasome. Although the nuclear receptor Rev-erbalpha attenuates the level of LPS-induced pulmonary inflammation, the mechanism remains unclear. In this study, we investigated the influence of LPS-induced production of IL-1beta and Rev-erbalpha on the development of lung inflammation. Herein, we demonstrate that Rev-erbalpha reduces IL-1beta production and lung injury following an intraperitoneal injection of LPS, which is dependent on the NF-kappaB/NALP3 pathway. Thus, Rev-erbalpha is able to decrease the extent of acute lung injury by regulating IL-1beta production. This mechanism may represent a potential novel therapeutic approach for lung injury. |
